Galmed unveils Aramchol LNP heart-targeting formulation in Barcode Nanotech collaboration
The company said the lipid nanoparticle approach redirects Aramchol beyond its usual 80-90% liver accumulation and could support disease-modifying therapies for cardiac fibrosis.